Clinical Trial Update: An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

This update reports results from a Phase 3 efficacy and safety study of vortioxetine for generalized anxiety disorder. The trial has completed and results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2013-12-18